BioSpace, a leading life sciences publication, featured Sigyn Therapeutics (OTC:SIGY) and its novel extracorporeal blood purification technology twice in January.
One article profiled the company and its Sigyn Therapy, a dual-function blood purification technology that extracts pathogen sources of life-threatening inflammation in concert with the broad-spectrum elimination of inflammatory mediators from the bloodstream. The “plug-and-play” device can be used with existing hemodialysis and CRT machines in hospitals.
The company is preparing an investigational device exemption to file with the FDA as a steppingstone to begin human studies of Sigyn Therapy.
A second BioSpace article examined how three companies, including Sigyn Therapeutics, are attempting to alleviate the problem of superbugs, or antibiotic-resistant bacteria. For his part, Sigyn CEO Jim Joyce discussed the potential benefit of combining Sigyn Therapy with anti-bacterial drugs to improve survival.
